[(123)I]MIBG is a better early marker of anthracycline cardiotoxicity than [(18)F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study

BACKGROUND: During anthracycline treatment of cancer, there is a lack for biomarkers of cardiotoxicity besides the cardiac dysfunction. The objective of the present study was to compare [(18)F]FDG and [(123)I]MIBG (metaiodobenzylguanidine) in a longitudinal study in a doxorubicin-induced cardiotoxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Oudot, Alexandra, Courteau, Alan, Guillemin, Mélanie, Vrigneaud, Jean-Marc, Walker, Paul Michael, Brunotte, François, Cochet, Alexandre, Collin, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452816/
https://www.ncbi.nlm.nih.gov/pubmed/34542689
http://dx.doi.org/10.1186/s13550-021-00835-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452816/
https://www.ncbi.nlm.nih.gov/pubmed/34542689
http://dx.doi.org/10.1186/s13550-021-00835-1

Ejemplares similares